CHEK1 and cancer: Altogether, these results demonstrate that the inhibition of CHK1 has a strong synergistic interaction with DNA-damaging agents, mainly platinum compounds but also gemcitabine, topotecan, and the novel PARP inhibitor olaparib on basal-like cancer cell lines.